Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
September 1, 2008
- Takeda to Become One of the Top-Three Oncology Companies: President Hasegawa
September 1, 2008
- Kyorin Obtains Encouraging PIIa Results with KRP-104
September 1, 2008
- Nisshin Seifun Withdraws from Ethical Drug Business by Selling Joint Venture to Kyorin
September 1, 2008
- AZ, SCC to Help Elimination of Drug Lag through Joint Research
September 1, 2008
- Prasugrel Inhibits Recurrence of CV Events More Effectively than Clopidogrel
September 1, 2008
- REGULATORY NEWS IN BRIEF
September 1, 2008
- MCHC Aims at Developing Comprehensive Healthcare Businesses: President Kobayashi
September 1, 2008
- Largest Number of Drugs Unavailable in Japan among 11 Countries: OPIR Survey
September 1, 2008
- Depression Linked to Changes in Cerebral Blood Flow
September 1, 2008
- Criteria for Use of Thalidomide Announced
September 1, 2008
- SAS Present in 1 out of 3 Type 2 Diabetics
September 1, 2008
- Toho Becomes a Major Shareholder of a Generic Maker
September 1, 2008
- Accused Surgeon Found Not Guilty by District Court
September 1, 2008
- Korosho to Demand Budget to Increase PMDA Staff Responsible for Safety Measures by 100
September 1, 2008
- JCR to Request Application for Higher Doses of MTX Based on Public Knowledge
September 1, 2008
- Yamato HD to Introduce New Direct Delivery System for Generics
September 1, 2008
- Doctors' Awareness Needs to Be Renovated to Popularize Biologics for RA
September 1, 2008
- Statistics／Drug Sales Up 0.7% in June: Crecon R&C
September 1, 2008
- No Evidence for Giving Priority to Iressa: CDFS
September 1, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…